| Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. | |
| | |
MedLine Citation:
|
PMID: 12591106 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We sought to assess how one tablet of non-enteric coated aspirin (325 mg) affects human platelets in subjects with risk factors for coronary artery disease. Data from 63 individuals with multiple cardiac risk factors were analyzed. Platelets were assessed twice at baseline (pre-aspirin), and after 3-4 h (post-aspirin). We employed 5 microM epinephrine-induced conventional aggregometry, closure time with epinephrine/collagen cartridge by PFA-100(R) (Dade-Behring), and aspirin response units (ARU) stimulated by propyl gallat with Ultegra (Accumetrics, San Diego, CA, USA) for measuring platelet function. In addition, the expression of platelet receptors was determined by using the following monoclonal antibodies: anti-CD31, CD41, CD42b, CD51/CD61, CD62p, CD63, CD107a, and CD151. Platelet-leukocyte formation was detected utilizing dual antibodies for a pan-platelet marker CD151, and CD14, a monocyte/macrophage marker. PAC-1 was used to measure fibrinogen-platelet binding. One pill of aspirin significantly decreased platelet-rich plasma (PRP) aggregation (74.18+/-16.75% vs. 24.92+/-8.64%; p<0.0001) and resulted in reduction of the aspirin response units (ARU) (662.24+/-65.65 vs. 451.05+/-69.31; p<0.0001). There was also prolongation of the closure time (194.4+/-25.3 vs. 258.63+/-55.61 s; p<0.0001). High correlation (r(2)=0.73-0.86) between platelet analyzer readings and aggregation was observed. One tablet of aspirin moderately inhibited expression of most surface platelet receptors measured, and such inhibition reached significance (p<0.05) for PAC-1, CD31, CD41, CD42, CD62p, and CD151. We conclude that a single dose of aspirin affects major platelet receptors, presumably directly or indirectly through the inhibition of prostanoids via platelet cyclooxygenase-1 blockade. The Ultegra Analyzer with a novel cartridge seems to be reliable in reflecting aspirins' effects on platelets and could be used in the future in clinical practice for monitoring aspirin therapy. |
| | |
Authors:
|
Alex I Malinin; Dan Atar; Kevin P Callahan; Marcus E McKenzie; Victor L Serebruany |
Related Documents
:
|
1342586 - Serotonin, histamine and platelets in vascular disease with special reference to periph... 12496056 - Inhibitory effects of sodium salicylate and acetylsalicylic acid on uvb-induced mouse s... 12569976 - Uncoupled regulation of leukotriene c4 synthase in platelets from aspirin-intolerant as... 3370916 - Inhibition of platelet aggregation and thromboxane production by low concentrations of ... 7813706 - Effect of recombinant human erythropoietin on platelets in patients with anemia of rena... 19467446 - P2x(1) receptor inhibition and soluble cd39 administration as novel approaches to widen... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: European journal of pharmacology Volume: 462 ISSN: 0014-2999 ISO Abbreviation: Eur. J. Pharmacol. Publication Date: 2003 Feb |
Date Detail:
|
Created Date: 2003-02-19 Completed Date: 2003-07-02 Revised Date: 2010-10-20 |
Medline Journal Info:
|
Nlm Unique ID: 1254354 Medline TA: Eur J Pharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 139-43 Citation Subset: IM |
Affiliation:
|
Center for Thrombosis Research, Sinai Hospital of Baltimore, Johns Hopkins University, 2401 West Belvedere Avenue, Schapiro Research Building R 202, Baltimore, MD 21215, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antigens, CD / blood, drug effects Antigens, CD14 / blood, drug effects Antigens, CD31 / blood, drug effects Aspirin / pharmacology* Coronary Artery Disease / blood*, prevention & control Female Flow Cytometry / instrumentation, methods Humans Integrin alphaV / blood, drug effects Lysosomal-Associated Membrane Protein 1 Lysosome-Associated Membrane Glycoproteins Male Middle Aged P-Selectin / blood, drug effects Platelet Aggregation / drug effects Platelet Aggregation Inhibitors / pharmacology* Platelet Glycoprotein GPIIb-IIIa Complex / drug effects, metabolism Platelet Membrane Glycoproteins / drug effects Risk Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD; 0/Antigens, CD14; 0/Antigens, CD31; 0/CD151 antigen; 0/CD63 antigen; 0/Integrin alphaV; 0/Lysosomal-Associated Membrane Protein 1; 0/Lysosome-Associated Membrane Glycoproteins; 0/P-Selectin; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Platelet Membrane Glycoproteins; 50-78-2/Aspirin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey.
Next Document: Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion.